Antonio Tito Fojo - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Antonio Tito Fojo's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Antonio Tito Fojo

Antonio Tito Fojo

Verified

Editor At Large, The Oncologist

United States

Final Covers

Tech

Journalist Type

Seniority Positions

Industries

Medium Formats

Content

Total articles 2

  • In Defense of Neuroendocrine Tumor Trials-Reply

    By Brian W. Labadie, Antonio Tito Fojo Verified| JAMA Oncology Verified In Reply We thank Strosberg and colleagues for their comments regarding our Viewpoint1 and acknowledge areas of agreement and disagreement. We agree on the pitfalls of progression-free survival (PFS) as an end point, not only in neuroendocrine cancers but in many diseases, and agree that the vulnerability of PFS as an end point can vary depending on the therapeutic being examined.

    By Brian W. Labadie, Antonio Tito Fojo Verified · JAMA Oncology

    Aug. 24, 2023

  • Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers

    By Brian W. Labadie, Antonio Tito Fojo Verified| JAMA Oncology Verified [Skip to Navigation] March 9, 2023 JAMA Oncol. Published online March 9, 2023.

    By Brian W. Labadie, Antonio Tito Fojo Verified · JAMA Oncology

    Mar. 12, 2023

  • In Defense of Neuroendocrine Tumor Trials-Reply

    By Brian W. Labadie, Antonio Tito Fojo Verified| JAMA Oncology Verified In Reply We thank Strosberg and colleagues for their comments regarding our Viewpoint1 and acknowledge areas of agreement and disagreement. We agree on the pitfalls of progression-free survival (PFS) as an end point, not only in neuroendocrine cancers but in many diseases, and agree that the vulnerability of PFS as an end point can vary depending on the therapeutic being examined.

    By Brian W. Labadie, Antonio Tito Fojo Verified · JAMA Oncology

    Aug. 24, 2023

As seen in

Company Info

The Oncologist

Oxford University Press (OUP) is the largest university press in the world and a department of the University of Oxford. Established in 1586, it has a rich history that began with the first book printed in Oxford in 1478. As a charitable organization, OUP focuses on educational advancement and ethical practices, reinvesting its surpluses into academic initiatives. OUP operates in over 50 countries, providing a wide range of products and services. It publishes scholarly journals, monographs, and reference works, including the renowned Oxford English Dictionary. The press also produces educational resources such as textbooks and digital learning tools for various educational levels, along with children's literature and religious texts, including the King James Authorized Version of the Bible. OUP is committed to sustainability and aims for carbon neutrality by 2050, while also addressing educational gaps and promoting accessibility for learners worldwide.